Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HBM Holdings Ltd. ( (HK:2142) ) has shared an announcement.
HBM Holdings Ltd. disclosed that independent non-executive director Dr. Xiaoping Ye is under investigation by the China Securities Regulatory Commission over alleged violations related to information disclosure on shareholding changes in Hangzhou Tigermed Consulting Co., Ltd. Dr. Ye, who does not participate in HBM’s day-to-day management, has pledged to cooperate with regulators and comply with disclosure rules.
The board said HBM’s operations remain normal and does not expect the probe to affect the group’s business, while promising further updates as the investigation progresses. Shareholders and potential investors have been urged to exercise caution when dealing in the company’s shares amid the ongoing regulatory inquiry.
The most recent analyst rating on (HK:2142) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
More about HBM Holdings Ltd.
HBM Holdings Ltd. is a Cayman Islands–incorporated company listed in Hong Kong, operating through a group structure. Its board consists of executive and independent non-executive directors, with oversight of the company’s strategic direction and compliance with Hong Kong listing and securities regulations.
Average Trading Volume: 3,391,318
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.72B
For detailed information about 2142 stock, go to TipRanks’ Stock Analysis page.